All In Biotech

Drug Trial Radar · NCT07697586

SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

206

Planned (sponsor's estimate)

Start

Aug 7, 2026

Primary completion

Aug 2028

Study completion Aug 2029

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.

Conditions

  • NSCLC

Interventions

  • SKB264+SKB118Drug

    Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: From enrollment to the end of treatment at 24 months
  2. ORR(objective response rate)Time frame: From enrollment to the end of treatment at 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jilin Cancer Hospital

    Jilin City, China · Not yet recruiting

  • Shanghai East Hospital, Tongji University

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.